Trasplante autólogo de precursores hematopoyéticos en pacientes mayores de 65 años, experiencia en un centro médico de Cali (Colombia).

Hematopoietic cell transplantation (HCT) aims to provide the recipient with a new hematopoietic system that works permanently, aiming at curing benign and neoplastic hematological diseases, if, like some solid tumors, at different ages, it is considered that older, older 65, is a relative contraindication. Objective: To describe the clinical characteristics and outcomes of patients who received a hematopoietic cell transplant over 65 years of age at a reference center in Cali. Materials and methods: A retrospective descriptive study based on the medical records of the entire autologous HCT population, from 2008 to 2013. Gender, age, comorbidities, Sorror index, hematologic recovery and mortality at day 100. Results: Thirteen patients were transplanted, 54% (7) men, 70% had a diagnosis of multiple myeloma, 30% (4) had hypertension, 97% of the patients had a low and intermediate Sorror index, 100, 2 patients died in relapse later. The median follow-up was 21 months. The most common complication associated with transplantation was mucositis, followed by febrile neutropenia. Conclusions: Bone marrow transplantation in patients over 65 years of age is an option for safe treatment; age should not be a limitation for its performance, since a good response rate with a low mortality is obtained.